
Panelist discusses how NALIRIFOX (liposomal irinotecan, 5-fluorouracil, leucovorin, oxaliplatin) represents a reasonable treatment option for patients with excellent performance status and locally advanced pancreatic adenocarcinoma, requiring close monitoring and proactive toxicity management to maximize outcomes.






